The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831.
Edith A. Perez
No relevant relationships to disclose
Steven M Butler
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Amylou C. Dueck
No relevant relationships to disclose
Frederick L. Baehner
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Farid Jamshidian
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Diana B. Cherbavaz
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
E Aubrey Thompson
No relevant relationships to disclose
Steven Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Peter Andrew Kaufman
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Nancy E. Davidson
No relevant relationships to disclose
Julie Gralow
Research Funding - Amgen; Genentech; Novartis; Roche
Yan W Asmann
No relevant relationships to disclose
Karla V. Ballman
No relevant relationships to disclose